Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

MARKSANS PHARMA LTD. - 524404 - Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants

 Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDl/162/2019 dated December 24, 2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021. Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended 31st March, 2022 is given in "Annexure A".
30-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

 As attached
30-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors

 As attached
30-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Investor Presentation Q4 & FY22
30-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Board Meeting Outcome for Outcome Of Board Meeting

 This is to inform you that the Board of Directors of the Company has, at its meeting held today i.e. Monday, 30th May, 2022 at Mumbai, recommended final dividend @ Re. 0.25 (Rupee Zero and Paise Twenty Five) i.e. 25% per equity share of Re. 1/- each face value for the financial year ended 31st March, 2022, subject to approval of the shareholders in the ensuing Annual General Meeting. The Book Closure/ Record Date for the Final dividend will be intimated in due course. The meeting commenced at 7:17 p.m. and concluded at 8:00 p.m.
30-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2022 And Auditors Report Thereon

 In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Audited Financial Results (both Standalone and Consolidated) for the quarter and financial year ended 31st March, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 30th May, 2022 along with Auditors Report thereon. The meeting commenced at 7:17 p.m. and concluded at 8:00 p.m. In this connection, we hereby confirm that the Statutory Auditors have given their reports on the Audited Annual Financial Results for the financial year ended 31st March, 2022 (both Standalone and Consolidated) with unmodified opinion.
30-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please find enclosed the Annual Secretarial Compliance Report for the financial year ended 31st March, 2022 issued by Mr. Jinesh Dedhia of Jinesh Dedhia & Associates, Practicing Company Secretaries.
26-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Intimation of Schedule of Q4&FY22 Results Conference Call.
24-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Change In Office Address Of Registrar And Transfer Agent Of The Company

 We we wish to inform you that the office address of our Registrar and Transfer Agent ('RTA') viz. Bigshare Services Private Limited has changed to and shall be operating from Office No S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai - 400 093. Please note that the e-mail address, telephone and fax numbers of the RTA shall continue to remain the same.
17-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Board to consider FY22 results & Dividend on May 30, 2022

 Marksans Pharma Ltd has informed BSE that the Meeting of the Board of Directors of the Company will be held on May 30, 2022, to consider and approve the Annual Audited Financial Results of the Company (both Standalone and Consolidated) for the Financial Year ended March 31, 2022. The Board of Directors will also consider recommendation of dividend, if any, forthe Financial Year 2021-22.Further, as per the Insider Trading Code of the Company, the Trading Window for dealing in Company''s shares has been closed for the Company''s insiders from April 01, 2022 and will remain closed till Forty-Eight hours after the announcement of the Financial Results on May 30, 2022.
16-05-2022
Next Page
Close

Let's Open Free Demat Account